REPLICor’s Data on REP 9C / REP 9AC Presented at the HEPDART Meeting

Laval, Quebec – Dec. 6^th, 2007 – The collaborative efforts of REPLICor and Dr. Jake Liang (Head, Liver Diseases Branch NIH / NIDDK) in the development of REPLICor’s lead compounds, REP 9C / REP 9AC, for the treatment of hepatitis C will be discussed by Dr. Liang during an invited presentation at the HEPDART 2007 meeting, to be held in Hawaii from December 9-13, 2007.  REPLICor has also been granted an oral presentation and a poster presentation to present its preclinical development data on the use of REP 9AC for the treatment of hepatitis B (generated in collaboration with Dr. Allison Jilbert, Infectious Diseases Laboratories, Adelaide).